Electrocardiography in the patient with the Wolff-Parkinson-White syndrome: diagnostic and initial therapeutic issues.
The Wolff-Parkinson-White syndrome (WPW), estimated to occur in approximately 0.1% to 3% of the general population, is a form of ventricular preexcitation involving an accessory conduction pathway. The definition of WPW relies on the following electrocardiographic features: (1) a PR interval less than 0.12 seconds (2) with a slurring of the initial segment of the QRS complex, known as a delta wave, (3) a QRS complex widening with a total duration greater than 0.12 seconds, and (4) secondary repolarization changes reflected in ST segment-T wave changes that are generally directed opposite (discordant) to the major delta wave and QRS complex changes. The accessory pathway bypasses the atrioventricular (AV) node, creating a direct electrical connection between the atria and ventricles. The majority of patients with preexcitation syndromes remain asymptomatic throughout their lives. When symptoms do occur they are usually secondary to tachyarrhythmias; the importance of recognizing this syndrome is that these patients may be at risk to develop a variety of supraventricular tachyarrhythmias which cause disabling symptoms and, in the extreme, sudden cardiac death. The tachyarrhythmias encountered in the WPW patient include paroxysmal supraventricular tachycardia (both the narrow QRS and wide QRS complex varieties), atrial fibrillation, atrial flutter, and ventricular fibrillation. Diagnostic and urgent, initial therapeutic issues based on initial electrocardiographic information are presented via 5 illustrative cases.
Rosner
M H
MH
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, USA.
Brady
W J
WJ
Kefer
M P
MP
Martin
M L
ML
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D004554:Electric Countershock; D004562:Electrocardiography / Q000379:methods*; D004638:Emergency Treatment / Q000379:methods*; D005260:Female; D006329:Heart Conduction System / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000627:therapeutic use; D013610:Tachycardia / Q000209:etiology*; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications* / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D011342:Procainamide